Alpine Global Management’s Alaunos Therapeutics TCRT Stock Holding History

Alpine Global Management’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-771	Closed	-$126K	–	697
2021 Q4	$126K	Buy	+771	New	+$169K	0.02%	591
2021 Q3	–	Sell	-110	Closed	-$43K	–	362
2021 Q2	$43K	Buy	+110	New	+$51.3K	0.01%	285
2020 Q1	–	Sell	-153	Closed	-$108K	–	418
2019 Q4	$108K	Buy	+153	New	+$105K	0.02%	354
2015 Q2	–	Sell	-67	Closed	-$108K	–	1252
2015 Q1	$108K	Buy	+67	New	+$99.3K	0.04%	296

Other funds holding TCRT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Alpine Global Management's TCRT Position: Q1 2022 in Review

Alpine Global Management sold out of Alaunos Therapeutics (TCRT) in Q1 2022, closing a stake of 771 shares — an estimated $126K sold.

Alpine Global Management first reported a position in TCRT in Q1 2015 and held it in 4 quarters. The position peaked at $126K in Q4 2021. 148 funds tracked by Wall St. Rank hold TCRT as of Q1 2022.

Alpine Global Management reported no remaining Alaunos Therapeutics position as of Q1 2022 after selling out during the quarter.
Alpine Global Management sold 771 Alaunos Therapeutics shares in Q1 2022, an estimated $126K.
Alpine Global Management first reported a position in Alaunos Therapeutics in Q1 2015 and held it in 4 quarters.
Alpine Global Management's Alaunos Therapeutics position peaked at $126K in Q4 2021.
148 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2022.

Based on Alpine Global Management's 13F filing for Q1 2022, filed 13 May 2022.